QIAGEN NV, a holding company based in the Netherlands, specializes in "Sample to Insight" solutions that convert biological samples into molecular knowledge.

The company offers an integrated approach that combines sampling and analysis technologies, bioinformatics, and automation systems to enhance molecular testing workflows.

QIAGEN's sampling technologies are designed to isolate and prepare DNA, RNA, and proteins from various sources, including blood, tissues, and plants.

Its assay technologies enable the visualization of these biomolecules for analysis, facilitating the identification of genetic information in pathogens and mutations in tumors.

Additionally, the company's bioinformatics solutions play a crucial role in interpreting data to yield actionable insights, while its automation platforms utilize polymerase chain reaction (PCR) and next-generation sequencing (NGS) technologies to streamline the entire process from sample collection to analysis.